Global regulatory readiness Cliantha has earned inspections from major global regulators (FDA, EU agencies, MHRA, ANVISA, NPRA, WHO, etc.), signaling robust quality systems and a track record that can reassure prospective clients seeking compliant CRO partnerships for multinational trials.

Expanded footprint With state-of-the-art sites and labs across India and North America and growth through strategic acquisitions, Cliantha offers broad geographic coverage and end-to-end development capabilities appealing to sponsors pursuing globally distributed studies.

Diverse service portfolio Offering Early Phase, Late Phase, Bioanalytical, IVRT/IVPT, Biometrics, Medical Services, Allergy Testing and Veterinary Therapeutics enables one-stop sourcing for sponsors, creating upsell opportunities across multiple trial needs.

Recent collaborations Recent partnerships with Social Palette Inc. for lead generation and with Intelligent Bio Solutions for PK studies indicate active business development and the potential for joint initiatives to expand client pipelines and study types.

Mid-market specialization With revenue in the 25–50 million range and a 1,500+ professional team, Cliantha sits in a mid-market CRO niche, offering compelling value for mid-sized pharma/biotech sponsors seeking cost-effective, high-quality outsourcing with global reach.